Targeting multimeric imaging agents through multilocus binding
A contrast agent and multi-site technology, which is applied in the field of contrast enhancement, new multi-body compounds, and contrast agents for diagnostic imaging, can solve the problems of increasing contrast, reducing flexibility, and large background of rigid contrast agents, so as to improve imaging contrast and imaging Effect of Contrast Improvement
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0152] Embodiment 1 measures the method for relaxation rate
[0153] The relaxivity of compounds of the invention was evaluated with a Bruker NMS-120 Minnispec NMR spectrophotometer operated at 0.47 Tesla (20 MHz H-1 Larmor frequency) and 37°C. The T of the water proton is determined by the inversion recovery pulse sequence using the software of the device 1 . Relaxation rates were determined in the presence of target (typically 4.5% HSA) by preparing 4 independent samples. The first contained only 4.5% HSA in phosphate buffered saline (PBS), the other three contained 20, 30 and 40 [mu]M Gd(III) in addition to 4.5% HSA in PBS, respectively. Incubate samples at 37 °C for at least 15 min to ensure T 1 Temperature equilibration before measurement. The content of Gd(III) in the samples was determined by inductively coupled plasma-mass spectrometry (ICP-MS). by s -1 The indicated relaxivity rate (1 / T1) was plotted against the Gd(III) concentration (mM) to determine the relaxi...
Embodiment 2
[0155] Example 2 Experimental model for testing fibrin binding contrast agent of the present invention
[0156] In these examples the contrast agent with high relaxivity and specificity for imaging blood clots (thrombosis) is able to distinguish blood clots from circulating fibrinogen. It can provide sensitive and effective detection of thrombus formation in various states of disease progression. It can be used to diagnose the presence of early and late thrombosis.
[0157] One animal model that can be used is the rabbit jugular vein thrombosis model (jugular vein clamped). The vein was clamped in two places, and the rabbit blood between the two clamps was removed. Human fibrinogen, rabbit red blood cells and thrombin were added between the two clamps to generate a thrombus containing human fibrin. Typically such thrombi are aged for 30 minutes.
[0158] In this rabbit jugular vein model, the conventional measuring instrument is 1.5 Tesla with spoiled gradient (spoiled gra...
Embodiment 3
[0159] Example 3 Example Compounds: Preparation
[0160] A preferred example of the present invention is a contrast agent for MRI imaging having the structure shown in FIG. 13 .
[0161] The contrast agent in Figure 13 contains 4 DTPA-Gd moieties used as IEMs. IEMs are attached to the ethylenediamine framework through a linker comprising a series of repeating amides. TBM are two peptides that exhibit high affinity for fibrin. These two peptides can be cyclized by forming a disulfide bond between two cysteine residues. TBM is attached to the framework by oxime and amide linkages.
[0162] At 37°C, 10μM contrast medium, 2.5mg / ml fibrin, 50mM Tris, 150mM NaCl, 2mM Ca 2+ , At pH 7.4, the combination of the prototype thrombus agent with the amino acid fragment of DD(E) in fibrin was 51%. The relaxation rate of the bound compound at 20MHz and 37°C is 101.4mM -1 the s -1 , each Gd chelate is 25.4mM -1 the s -1 . The relaxation rate of free contrast agent is 67.7mM -1 t...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com